Cadila Pharmaceuticals is an Indian multinational pharmaceutical company based in

Ahmedabad Ahmedabad ( ; Gujarati: Amdavad ) is the most populous city in the Indian state of Gujarat. It is the administrative headquarters of the Ahmedabad district and the seat of the Gujarat High Court. Ahmedabad's population of 5,570,585 (per t ...

, Gujarat, India. The company's operations focus on manufacturing products ranging from API's-Intermediates, finished formulations, OTC-Food Supplements, Biotechnology Products and pharmaceutical Machinery. Cadila Pharmaceuticals manufacturing facilities are approved by International bodies such as WHO-GMP, UK-MHRA, USFDA-API, TGA-Australia, and AIFA-Italy. The company's international operation of is spread across 58 countries including the Americas, Japan, Asia, CIS and Africa.

History

Cadila Laboratories

In 1951 Indravadan A Modi had quit his job as a chemist in a Mumbai firm to start Cadila Laboratories with childhood friend Ramanbhai Patel. The company started in a rented bungalow with a capital of Rs 25,000 and achieved a turnover of around Rs 1.25 lakh in its first year of operation.

1995: Birth of Cadila Pharmaceuticals

The Modi and Patel families decided to split the business in 1995, two entities were formed - Cadila Pharmaceuticals Ltd (owned and controlled by Shri. I A Modi and his son Dr. Rajiv Modi) and

Cadila Healthcare Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad, which is primarily engaged in the manufacture of generic drugs. It ranked 100th in the Fortu ...

(owned by Shri. Ramanbhai Patel and his son Pankaj Patel family). Rajiv Modi and I A Modi worked closely to run Cadila Pharma, now considered one of the largest privately held pharma companies in the country.

Operations

Cadila Pharmaceuticals has its formulation manufacturing facilities at Dholka, Gujarat (India); Samba, Jammu (India) and at Addis Ababa (Ethiopia) and 2 API manufacturing facilities are located at Ankleshwar, Gujarat. The manufacturing facility at Dholka and the API unit at Ankleshwar in Gujarat are USFDA-certified; the overseas manufacturing facility at Ethiopia is the WHO - cGMP compliant facility.

Research

Cadila Pharmaceuticals has established a dedicated R&D facility, spread over 1,05,000 sq. ft. area at Dholka, Gujarat, India which is staffed by 300 scientists. The company has five IND dossiers filed with the USFDA for pulmonary tuberculosis, lung cancer, prostate cancer, bladder cancer and melanoma. The company has submitted ten ANDAs. Cadila Pharmaceuticals has connections with various institutions for research; Department of Biotechnology, UDSC, New Delhi; IISc, Bangalore; Lala Ram Sarup Institute of TB & Respiratory diseases, New Delhi; RRL, Jammu; CSIR, New Delhi; CDRI, Lucknow; Advanced Transfusion Medicine Research Foundation, Ahmedabad; National Institute of Immunology, New Delhi; Institute of Microbial Technology, Chandigarh; Talwar Research Foundation, New Delhi and Trieste, Italy.

Products and services

Cadila Pharmaceuticals is the only Indian manufacturer of natural Streptokinase and Hyaluronic Acid products. The company was also the first in the world to introduce Rabeprazole in IV form – 'Rabeloc'. In 2009, the world's first boosted-Rifampicin fixed-dose combination for the treatment of Tuberculosis – 'Risorine' and world's first drug combination for prevention of Cardiovascular Diseases –
Polycap
were introduced by Cadila Pharmaceuticals. For the patients with Non Small Cell Lung Cancer (NSCLC), the company introduced 'Mycidac-C' - first in the class active immunotherapy as well as drug targeting Desmocollin. Some of the top brands of the company are Aciloc, Envas, Calcirol, Haem Up, Vasograin, Tricort, Fludac, Rabiloc, Trigan-D, Mycobutol and

Sepsivac Sepsivac is a drug developed by Cadila Pharmaceuticals to treat gram-negative sepsis. The active ingredient is heat-killed Mycobacterium w, a non-pathogenic strain of ''Mycobacterium''. As an immunomodulatory, it modulates the immune system of ...

Alliances

In 2019, Cadila Pharmaceuticals formed a partnership with Norwegian start-up, Serca Pharmaceuticals to develop new treatment for heart patients.

Awards and recognition

Most Trusted Companies of 2008, Sara Media and Zee Business WorldStar Packaging Award, 2018 TISS LeapVault CLO Award, 2019 Observenow Future of Workplace Award, 2019 Great Place to Work Certified, 2020

References

{{reflist Companies based in Ahmedabad Pharmaceutical companies established in 1951 Pharmaceutical companies of India Indian brands 1951 establishments in Bombay State